Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance

Severe Sepsis and Septic Shock Clinical Trial

Official title:
Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance

Status Recruiting

Clinical Trial Summary

Microparticules (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with merging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This a prospective observational study of circulating MPs and blood coagulation in septic shock patients admitted in medical intensive care units (ICUs) of four tertiary hospitals at baseline (D1, D2, D3, D4, D7).

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02391792
Study type	Observational [Patient Registry]
Source	University Hospital, Strasbourg, France
Contact	Ferhat MEZIANI, MD, PhD
Email	ferhat.meziani@chru-strasbourg.fr
Status	Recruiting
Phase	N/A
Start date	March 2013
Completion date	March 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02030158` - Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock
Recruiting	`NCT02300415` - Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.	N/A
Completed	`NCT00818597` - Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients	Phase 1/Phase 2